New hope for Hodgkin's lymphoma after BMT failure

Adcetris (brentuximab vedotin) is now approved for patients with progressive Hodgkin's lymphoma after bone marrow transplant and for patients with anaplastic large cell lymphoma who progressed after multiple lines of previous chemotherapies. Adcetris is a combination of an antibody which attacks the CD30 receptor and an anti-tumor drug, thus two modes of attack within one treatment.